Cargando…
SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
Although infections among vaccinated individuals lead to milder COVID-19 symptoms relative to those in unvaccinated subjects, the specificity and durability of antibody responses elicited by breakthrough cases remain unknown. Here, we demonstrate that breakthrough infections induce serum-binding and...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769922/ https://www.ncbi.nlm.nih.gov/pubmed/35123650 http://dx.doi.org/10.1016/j.cell.2022.01.011 |
_version_ | 1784635250687606784 |
---|---|
author | Walls, Alexandra C. Sprouse, Kaitlin R. Bowen, John E. Joshi, Anshu Franko, Nicholas Navarro, Mary Jane Stewart, Cameron Cameroni, Elisabetta McCallum, Matthew Goecker, Erin A. Degli-Angeli, Emily J. Logue, Jenni Greninger, Alex Corti, Davide Chu, Helen Y. Veesler, David |
author_facet | Walls, Alexandra C. Sprouse, Kaitlin R. Bowen, John E. Joshi, Anshu Franko, Nicholas Navarro, Mary Jane Stewart, Cameron Cameroni, Elisabetta McCallum, Matthew Goecker, Erin A. Degli-Angeli, Emily J. Logue, Jenni Greninger, Alex Corti, Davide Chu, Helen Y. Veesler, David |
author_sort | Walls, Alexandra C. |
collection | PubMed |
description | Although infections among vaccinated individuals lead to milder COVID-19 symptoms relative to those in unvaccinated subjects, the specificity and durability of antibody responses elicited by breakthrough cases remain unknown. Here, we demonstrate that breakthrough infections induce serum-binding and -neutralizing antibody responses that are markedly more potent, durable, and resilient to spike mutations observed in variants than those in subjects who received only 2 doses of vaccine. However, we show that breakthrough cases, subjects who were vaccinated after infection, and individuals vaccinated three times have serum-neutralizing activity of comparable magnitude and breadth, indicating that an increased number of exposures to SARS-CoV-2 antigen(s) enhance the quality of antibody responses. Neutralization of SARS-CoV was moderate, however, underscoring the importance of developing vaccines eliciting broad sarbecovirus immunity for pandemic preparedness. |
format | Online Article Text |
id | pubmed-8769922 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87699222022-01-20 SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses Walls, Alexandra C. Sprouse, Kaitlin R. Bowen, John E. Joshi, Anshu Franko, Nicholas Navarro, Mary Jane Stewart, Cameron Cameroni, Elisabetta McCallum, Matthew Goecker, Erin A. Degli-Angeli, Emily J. Logue, Jenni Greninger, Alex Corti, Davide Chu, Helen Y. Veesler, David Cell Article Although infections among vaccinated individuals lead to milder COVID-19 symptoms relative to those in unvaccinated subjects, the specificity and durability of antibody responses elicited by breakthrough cases remain unknown. Here, we demonstrate that breakthrough infections induce serum-binding and -neutralizing antibody responses that are markedly more potent, durable, and resilient to spike mutations observed in variants than those in subjects who received only 2 doses of vaccine. However, we show that breakthrough cases, subjects who were vaccinated after infection, and individuals vaccinated three times have serum-neutralizing activity of comparable magnitude and breadth, indicating that an increased number of exposures to SARS-CoV-2 antigen(s) enhance the quality of antibody responses. Neutralization of SARS-CoV was moderate, however, underscoring the importance of developing vaccines eliciting broad sarbecovirus immunity for pandemic preparedness. Elsevier Inc. 2022-03-03 2022-01-20 /pmc/articles/PMC8769922/ /pubmed/35123650 http://dx.doi.org/10.1016/j.cell.2022.01.011 Text en © 2022 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Walls, Alexandra C. Sprouse, Kaitlin R. Bowen, John E. Joshi, Anshu Franko, Nicholas Navarro, Mary Jane Stewart, Cameron Cameroni, Elisabetta McCallum, Matthew Goecker, Erin A. Degli-Angeli, Emily J. Logue, Jenni Greninger, Alex Corti, Davide Chu, Helen Y. Veesler, David SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses |
title | SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses |
title_full | SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses |
title_fullStr | SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses |
title_full_unstemmed | SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses |
title_short | SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses |
title_sort | sars-cov-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769922/ https://www.ncbi.nlm.nih.gov/pubmed/35123650 http://dx.doi.org/10.1016/j.cell.2022.01.011 |
work_keys_str_mv | AT wallsalexandrac sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses AT sprousekaitlinr sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses AT bowenjohne sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses AT joshianshu sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses AT frankonicholas sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses AT navarromaryjane sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses AT stewartcameron sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses AT cameronielisabetta sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses AT mccallummatthew sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses AT goeckererina sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses AT degliangeliemilyj sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses AT loguejenni sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses AT greningeralex sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses AT cortidavide sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses AT chuheleny sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses AT veeslerdavid sarscov2breakthroughinfectionselicitpotentbroadanddurableneutralizingantibodyresponses |